Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5(+) colorectal cancer

Detalles Bibliográficos
Autores principales: Feng, Haoran, Liu, Kun, Shen, Xiaonan, Liang, Juyong, Wang, Changgang, Qiu, Weihua, Cheng, Xi, Zhao, Ren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683607/
https://www.ncbi.nlm.nih.gov/pubmed/33230188
http://dx.doi.org/10.1038/s41419-020-03208-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683607/
https://www.ncbi.nlm.nih.gov/pubmed/33230188
http://dx.doi.org/10.1038/s41419-020-03208-z

Ejemplares similares